CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Hydroxychloroquine Sulfate + AzithromycinWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug166 CYNK-001 Wiki 1.00
drug375 Hydroxychloroquine Sulfate Wiki 0.32

Correlated MeSH Terms (14)

Name (Synonyms) Correlation
D007154 Immune System Diseases NIH 1.00
D030341 Nidovirales Infections NIH 0.71
D012327 RNA Virus Infections NIH 0.71
D003333 Coronaviridae Infections NIH 0.58
D008171 Lung Diseases, NIH 0.50
D012140 Respiratory Tract Diseases NIH 0.38
D012141 Respiratory Tract Infections NIH 0.26
D011024 Pneumonia, Viral NIH 0.17
D003141 Communicable Diseases NIH 0.12
D014777 Virus Diseases NIH 0.11
D011014 Pneumonia NIH 0.08
D007239 Infection NIH 0.08
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19

This is a three-arm randomized trial comparing the efficacy of single agent hydroxychloroquine to the combination of hydroxychloroquine and azithromycin, and to a delayed hydroxychloroquine regimen, which will serve as a contemporaneous Day 1-6 supportive care control, in eliminating detectable SARS-CoV-2 on day 6 following the initiation of treatment in order to determine which regimen is more effective.

NCT04336332 SARS-CoV-2 COVID-19 Combination Product: Hydroxychloroquine Sulfate + Azithromycin Drug: Hydroxychloroquine Sulfate

Primary Outcomes

Description: Will be assessed at day six compared to baseline between hydroxychloroquine sulfate alone and hydroxychloroquine sulfate plus azithromycin to treat COVID-19.

Measure: Changes in patients viral load

Time: Baseline, day 3 and day 6

Description: A second concurrent comparison will evaluate change in viral load at day 6 between hydroxychloroquine sulfate alone and supportive care.

Measure: Second evaluation of changes in patients viral load

Time: Day 6

Secondary Outcomes

Description: Time to resolution of symptoms

Measure: Symptom questionnaire

Time: up to 6 months

Description: Change in the fever curve resulting in shorter time to afebrile for 48 hours

Measure: Fever assessment

Time: up to 10 days

Description: Body temperature will be measured in degrees Fahrenheit using an automated thermometer which will be provided to the patient 4 times per day.

Measure: Vital Signs - Body Temperature

Time: up to 10 days

Description: Time to discharge (If hospitalized)

Measure: Discharge

Time: up to 6 months

Description: Time to recovery (back to school, work, etc)

Measure: Recovery

Time: up to 6 months

Description: As measured by standard metrics

Measure: Assessment of agent toxicity

Time: up to 10 days

Description: Collection of Oropharynx swabs for viral load and microbiome analysis

Measure: Oropharynx swab sample collections

Time: up to 10 days

Description: Collection of blood for viral load and microbiome analysis

Measure: Blood Sample collections

Time: up to 10 days

Description: Decrease in virus shedding in nasopharyngeal secretions such as Ferritin, D-dimer, CRP, Troponin and LDH

Measure: Viral shedding assessment - nasopharyngeal secretions

Time: up to 10 days

Description: Decrease in virus shedding in serology such as Ferritin, D-dimer, CRP, Troponin and LDH

Measure: Viral shedding assessment - serology

Time: up to 10 days

Description: Measurement of cytokines in blood

Measure: Cytokines in blood

Time: up to 10 days

No related HPO nodes (Using clinical trials)